Recombinant T-cell receptor ligand (RTL) for treatment of multiple sclerosis: A double-blind, placebo-controlled, phase 1, dose-escalation study

Vijayshree Yadav, Dennis N. Bourdette, James D. Bowen, Sharon G. Lynch, David Mattson, Jana Preiningerova, Christopher T. Bever, Jack Simon, Andrew Goldstein, Gregory G. Burrows, Halina Offner, Al J. Ferro, Arthur A. Vandenbark

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Fingerprint

Dive into the research topics of 'Recombinant T-cell receptor ligand (RTL) for treatment of multiple sclerosis: A double-blind, placebo-controlled, phase 1, dose-escalation study'. Together they form a unique fingerprint.

Medicine & Life Sciences